Hydrogel-forming microneedles enhance transdermal delivery of metformin hydrochloride by Migdadi, Eman M. et al.
Contents lists available at ScienceDirect
Journal of Controlled Release
journal homepage: www.elsevier.com/locate/jconrel
Hydrogel-forming microneedles enhance transdermal delivery of metformin
hydrochloride
Eman M. Migdadia,b, Aaron J. Courtenaya, Ismaiel A. Tekkoa,c, Maelíosa T.C. McCruddena,
Mary-Carmel Kearneya, Emma McAlistera, Helen O. McCarthya, Ryan F. Donnellya,⁎
a School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7BL, UK
b School of Pharmacy, Applied Science Private University, Amman, Jordan
c School of Pharmacy, University of Aleppo, Aleppo, Syria
A R T I C L E I N F O
Keywords:
Metformin HCl
Hydrogel-forming microneedles
Transdermal delivery
A B S T R A C T
We investigated, for the ﬁrst time, the potential for a hydrogel-forming microneedle (MN) patch to deliver the
high-dose drug metformin HCl transdermally in a sustained manner. This may minimize some gastrointestinal
side eﬀects and small intestine absorption variations associated with oral delivery. Patches (two layers) were
assembled from a lyophilised drug reservoir layer, with the MN layer made from aqueous blend of 20% w/w poly
(methylvinylether-co-maleic acid) crosslinked by esteriﬁcation with 7.5% w/w poly (ethylene glycol)
10,000 Da.> 90% of metformin was recovered from homogeneous drug reservoirs. Drug reservoir dissolution
time in PBS (pH 7.4) was<10min. MN penetrated a validated skin model Paraﬁlm®M consistently. Permeation
of metformin HCl across dermatomed neonatal porcine skin in vitro was enhanced by using MN. The combined
MN and metformin HCl reservoir patch (containing 75mg or 50mg metformin HCl, respectively) delivered
9.71 ± 2.22mg and 10.04 ± 1.92 mg at 6 h, respectively, and 28.15 ± 2.37mg and 23.25 ± 3.58mg at
24 h, respectively.In comparison, 0.34 ± 0.39mg and 0.85 ± 0.68mg was delivered at 6 h, respectively, and
0.39 ± 0.39mg and 1.01 ± 0.84mg was delivered at 24 h, respectively, from a control set-up employing only
the drug reservoirs. In vivo, metformin HCl was detected in rat plasma at 1 h post MN application at a con-
centration of 0.62 ± 0.51 μg/mL, increasing to 3.76 ± 2.58 μg/ml at 3 h. A maximal concentration of
3.77 ± 2.09 μg/ml was achieved at 24 h. Css was 3.2 μg/mL. Metformin transdermal bioavailability using MNs
was estimated as 30%.Hydrogel-forming MN are a promising technology that has demonstrated successful
transdermal delivery of metformin HCl. Potential clearly exists for administration of other high-dose drugs using
this system.
1. Introduction
Hydrogel-forming microneedle arrays (MNs) are typically fabricated
from aqueous blends of poly (methylvinylether/maleic acid) and poly
(ethylene glycol) via a micromoulding process using silicone moulds
that have been prepared by laser engineering technology [1,2]. Hy-
drogel-forming MNs, contain no drug themselves, but swell in skin to
allow diﬀusion of drug contained in an attached reservoir layer to the
dermal microcirculation for systemic absorption [1]. Many studies have
demonstrated the ability of hydrogel-forming MNs to enhance trans-
dermal delivery of a variety of molecules, such as small hydrophilic
drugs, including caﬀeine, theophylline, methylene blue and me-
tronidazole [1]. In addition, high molecular weight substances, such as
insulin and bovine serum albumin [1] and high-dose drugs, like ibu-
profen [3] and, recently, donepezil have also been delivered [4].
Hydrogel-forming MNs, once applied to the skin, can be withdrawn
intact, leaving no polymeric residues behind. This represents a con-
siderable advantage in comparison to dissolving MNs [5]. Hydrogel-
forming MNs do not become blocked by compressed dermal tissue upon
application, in comparison to hollow MNs [1]. Hydrogel-forming MNs
could overcome some of the limitations typically associated with coated
MNs, such as extremely reduced MN loading capacity, diﬃculty in
achieving accurate drug coating and controlling rate and extent of drug
release [1]. This technology oﬀers a simpliﬁed one-step application
process, in comparison to uncoated solid MNs that require a two-step
application [1].
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The use of hydrogel-forming MNs is not restricted to drug delivery.
The capability of these MNs to imbibe skin interstitial ﬂuid (ISF) implies
that these MNs could be used to extract drug molecules of interest from
the skin for subsequent analysis. Drug concentrations in ISF often re-
ﬂect those in plasma [6], so this technology could prove of great use in
blood-free patient drug monitoring and may overcome many limita-
tions associated with direct blood sampling. This is expected to be ad-
vantageous for speciﬁc patients, such as neonates and the elderly [5].
Indeed, hydrogel-forming MN arrays have been used for successful
extraction and quantiﬁcation of drug substances, such as theophylline,
caﬀeine, glucose and lithium from skin in vitro and in vivo [7,8].
Metformin HCl [1, 1-dimethyl biguanide hydrochloride] is the most
widely prescribed drug for treatment of individuals with type II dia-
betes mellitus. It is recommended, in combination with lifestyle mod-
iﬁcation (diet, weight control and physical activity), as a ﬁrst line oral
therapy [9,10,21]. Metformin HCl acts by minimizing insulin re-
sistance, particularly in the liver and in skeletal muscle. It inhibits he-
patic gluconeogenesis, increases peripheral insulin sensitivity in in-
sulin-sensitive tissues, such as adipose tissue and muscle and enhances
peripheral glucose utilisation [11–14].The most severe side eﬀect of
metformin relates to its association with lactic acidosis, particularly in
patients with renal and cardiac impairment. Metformin HCl can also
cause signiﬁcant gastrointestinal side eﬀects, including vomiting,
diarrhoea, abdominal pain, drowsiness, stomach pain, ﬂatulence and
loss of appetite [15].
Recent evidence has indicated that the gastrointestinal tract is an
important site of action of metformin HCl. Metformin increases glucose
uptake and utilisation in the human intestine, resulting in an increase in
lactate production in enterocytes [16,17]. However, the gastrointestinal
tract is also the site of an important adverse reaction to metformin,
which is the intolerance that often limits metformin dosing or use
completely. Metformin intolerance may relate to diﬀerent mechanisms,
including altered transport of serotonin or histamine, local metformin
accumulation in enterocytes, increased bile acid exposure in the colon
and altered gut microbiome [18,19]. The reduction in bile acid ab-
sorption has been suggested as a mechanism through which chronic
metformin treatment can lower cholesterol levels [20,21]. It has also
been suggested that an increased luminal bile salt concentration would
have an osmotic eﬀect, which could lead to the diarrhoea associated
with metformin treatment [20].
Metformin HCl is a low potency, high-dose drug [22]. It can be
prescribed as 500mg, 850mg and 1000mg tablets. In adults, it is often
started at the 500-mg dose and increased weekly until the maximum
tolerated dose is achieved, normally 2 g/day, depending upon patient
response.It has a reported oral bioavailability of 50–60% under fasting
conditions [23]. However, metformin HCl is generally recommended to
be taken with meals, as it decreases glucose absorbance. Notably,
though, food decreases the absorption of metformin HCl in the small
intestine [23], which can result in variations in absorption proﬁle and,
in turn, glucose control.
This study investigates the ability of hydrogel-forming MNs to de-
liver metformin HCl transdermally in vitro and in vivo. Hydrogel-
forming MNs may allow transdermal delivery of metformin HCl in a
sustained fashion, which may in turn help minimize some gastro-
intestinal side eﬀects and avoid the small intestine absorption varia-
tions associated with the oral delivery route.
2. Materials and methods
2.1. Materials
Gantrez® S-97, which is poly (methylvinylether/maleic acid)
(PMVE/MA) with molecular mass of 1,500,000 Da was a gift from
Ashland, Kidderminster, UK.Poly (ethylene glycol) (PEG), molecular
weight 10,000 Da, was purchased from Sigma-Aldrich, Steinheim,
Germany. Sodium carbonate (Na2CO3) was purchased from BDH
Laboratory Supplies, London, UK. HPLC grade methanol, acetonitrile
and triethylamine were purchased from Sigma Aldrich, Dorset, UK.
Metformin HCl was purchased from Tokyo Chemical Industry Co., LTD,
Tokyo, Japan. Cryogel SG3 gelatin was purchased from PB Gelatins,
Pontypridd, UK. Pearlitol® 50C-Mannitol was purchased from Roquette,
Lestrem, France. Depilatory cream (Boots Expert®) was purchased from
The Boots Company PLC, Nottingham, UK. Paraﬁlm® M was purchased
from Bemis, Neenah, USA. All other chemicals used were of analytical
reagent grade.
2.2. Fabrication of hydrogel-forming microneedles (MNs)
An aqueous stock solution of 40% w/w of Gantrez® S-97 (PMVE/
MA) was prepared and used to produce a blend containing 20% w/w of
Gantrez® S-97, 7.5% w/w of PEG 10,000 and 3% w/w of Na2CO3 in
deionized water. This gel (0.5 g) was carefully poured into pre-formed
silicone moulds (11× 11 needle array density, 600 μm height, 300 μm
width at the base and 150 μm interspacing) and the aluminum lid
screwed on, before being centrifuged for 15min at 3500 rpm. After
centrifugation, the nascent MNs were dried at room temperature for
48 h. The micromoulds containing the formed MN were then heated at
80 °C for 24 h to induce ester-based crosslinking between PEG and
PMVE/MA. Upon cooling, the silicone moulds containing the PEG-
PMVE/MA MN arrays were removed from the aluminum holder and the
silicone moulds were then peeled away. The sidewalls formed by the
moulding process were removed using a heated blade, as described
previously [1,3,24].
2.3. Mechanical strength of MNs
An axial compression load was applied to the MN arrays (11×11)
using a TA. XT-plus Texture Analyser (TA, Stable Micro System, Surrey,
UK), (Fig. 1 (i)). MN arrays were attached to the moving testing probe
of the TA using double-sided adhesive tape (Henkel Ltd., Cheshire, UK).
The test station pressed MN arrays against a ﬂat block of aluminum
with diﬀerent compression forces of 0.05, 0.1, 0.2 and 0.3 N/needle for
30 s at a rate of 0.5mm/s. Pre-test and post-test speeds were 1.0 mm/s
and the trigger force was 0.049 N. All MNs of each array were visually
examined using the digital microscope (Leica EZ4W, Leica, Wetzlar,
Germany). The height of the MNs before and after testing were mea-
sured using the software of the digital microscope and the percentage
change in the MN height was calculated [1–3,24].
2.4. Skin insertion study using optical coherence tomography
The penetration properties of MN arrays into a validated skin
model, Paraﬁlm® M [25], were studied using an optical coherence to-
mography (OCT) microscope (Michelson Diagnostics Ltd., Kent, UK). A
sheet of Paraﬁlm® M was folded to yield an eight-layer ﬁlm (1.0mm
thickness), placed on a sheet of poly(ethylene) (for support) and cov-
ered with aluminum foil. The MN arrays were placed this assembled
ﬁlm of Paraﬁlm® M and ﬁxed in place using adhesive tape. The inser-
tion of MN arrays was carried out manually using thumb pressure for an
application period of 30 s. The inserted MNs were immediately visua-
lised using the OCT microscope. The swept-source Fourier domain OCT
system has a laser center wavelength of 1305.0 ± 15.0 mm, facilitating
real-time high-resolution imaging. The images were analysed using the
imaging software ImageJ® (National Institutes of Health, Bethesda,
USA). The scale of the image ﬁles obtained was 1.0 pixel= 4.2 μm. OCT
is employed to allow accurate measurements of the distance between
the lower MN base plate and the skin's stratum corneum (SC) (a), the
depth of MN penetration (b) and the width of pore created (c) (Fig. 1
(iii)). The insertion of 12 individual MNs was measured [1–3,24,25].
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2.5. Fabrication of lyophilised metformin HCl reservoirs
Metformin HCl-loaded drug reservoirs were fabricated using
varying concentrations of metformin HCl, gelatin, mannitol and deio-
nized water (Table 1). The components were hand-mixed and then
sonicated at 37 °C for 60min. The resulting formulations were cast
(300mg, 150mg or 100mg) into open-ended cylindrical moulds with a
diameter of 8mm and depth 4mm, then frozen at −80 °C for a
minimum of 60min. Formulations were then lyophilised in the freeze
drier (Virtis™ Advantage XL-70 bench top lyophiliser, SP Scientiﬁc®,
Pennsylvania, USA), according to the following regime: Primary drying
for 90min at a shelf temperature of−40 °C, drying for 90min at a shelf
temperature of −30 °C, drying for 90min at a shelf temperature of
−20 °C, drying for 530min at a shelf temperature of−10 °C, drying for
90min at a shelf temperature of 0–10 °C. Secondary drying was carried
out for 660min at a shelf temperature of 25 °C and a vacuum pressure
of 50mTorr [21].
2.6. Characterisation of lyophilised metformin HCl reservoirs
Lyophilised metformin HCl reservoirs were characterised visually
using the digital microscope. The reservoir thickness was measured
using the software of the digital microscope. The time to complete
dissolution of the reservoir in PBS (pH 7.4) was determined visually by
placing one reservoir of each formula in 20ml of PBS (pH 7.4) and
recording the dissolution time.
2.7. The eﬀect of lyophilisation on metformin HCl stability
Lyophilised reservoirs, three of formula F6 (containing 75mg met-
formin HCl) and three of formula F13 (containing 50mg metformin
HCl) were placed in individual vials containing 20ml of PBS (pH 7.4)
and stirred using a magnetic stirrer at 200 rpm. After complete dis-
solution, samples were taken, ﬁltered through 0.2 μm ﬁlters and ap-
propriately diluted. Samples were analysed by the validated HPLC
method detailed below and the percentage recovery of metformin HCl
was calculated.
2.8. In vitro permeation of metformin HCl
Franz diﬀusion cells were used to assess permeation of metformin
HCl from lyophilised reservoirs through hydrogel-forming MNs and
across dermatomed neonatal porcine skin. Skin samples were obtained
from stillborn piglets and immediately (< 24 h after birth) excised,
trimmed to the desired thickness (approximately 350 μm) using an
electric dermatome (Integra Life Sciences™, Padgett Instruments, NJ,
USA) and frozen at−20 °C until use. MN arrays, (11×11 needle array
density, 600 μm height, 300 μm width at the base and 150 μm
Fig. 1. (i) Measuring the mechanical strength of MNs using the Texture Analyser (TA). (ii) Representative bar chart of percentage reduction in the height of needles of
MNs measured following the application of diﬀerent forces using the Texture Analyser (means ± SD, n=3). (iii) Diagrammatic representation of the measurements
that are possible from the optical coherence tomographic images of MN penetration into skin, namely; a, the distance between the lower MN base plate and the
stratum corneum (SC); b, the depth of MN penetration into the skin; and c, the width of the micropore created.(iv) The insertion of MNs array in Paraﬁlm® M using
OCT.
Table 1
Formulations of metformin HCl-containing drug reservoirs.
Formula (F)
number
Metformin
HCl (%w/w)
Gelatin
(%w/w)
Mannitol
(%w/w)
Water
(%w/w)
Formula
weight (mg)
F1 40 10 13 47 300
F2 40 10 13 47 150
F3 45 7 3 45 300
F4 45 7 3 45 150
F5 50 5 3 42 300
F6 50 5 3 42 150
F7 35 10 3 52 300
F8 35 10 3 52 150
F9 30 15 3 52 300
F10 30 15 3 52 150
F11 55 5 2 38 300
F12 55 5 2 38 150
F13 50 5 3 42 100
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interspacing), were inserted using manual pressure for 30 s. PBS
(pH 7.4), 20 μL was then placed on the top of the array to promote
adhesion of the lyophilised reservoir, containing either 75mg (F6) or
50mg (F13) of metformin HCl, to the MN baseplate. A cylindrical
stainless steel weight (11.0 g) was placed on top of the MN array to
prevent MN expulsion and the donor compartment of the apparatus was
then clamped onto the receiver compartment. The donor compartment
and sampling arm were sealed using Paraﬁlm® M. The receiver com-
partment contained 12.1ml of PBS (pH 7.4), degassed prior to use and
pre-heated to 37 °C ± 1 °C. This ensures complete contact between
receiver ﬂuid and porcine skin. Syringes (1.0 mL) with 8.0 cm needles
were used to remove 200 μL of the Franz cell contents at pre-de-
termined time intervals and pre-warmed PBS (pH 7.4) was subsequently
added to replace this. Control Franz cells were assembled in the same
manner, but without the application of MN arrays. Instead, the drug-
loaded reservoir was applied directly to the dermatomed porcine skin.
All samples were centrifuged at 14,000 rpm using an Eppendorf
MiniSpin® centrifuge (Eppendorf UK Limited, Stevenage, UK) for
10min and diluted prior to HPLC analysis [3,4].
2.9. In vivo study
Female Sprague-Dawley rats weighing 230.67 ± 17.05 g were ac-
climatized for 7 days prior to the in vivo study. Animals were separated
into two groups (n=8 per group). In the oral control group, animals
received an oral solution of metformin HCl (100mg/kg) based on in-
dividual rat weight, [26]. The second group was the MNs transdermal
treatment group, in which rats were treated with two hydrogel-forming
MN patches. To minimize interference of rat hair with MN application
in the second group, it was removed from the back region 4 h prior to
the experiment. Firstly, electric hair clippers were used to remove the
bulk hair, then depilatory cream was applied to remove any residual
hair that may otherwise interfere with MNs insertion [1,27]. To facil-
itate MN application, rats were sedated using gas anesthesia (2–4% (v/
v) isoﬂurane in oxygen). Rat skin was pinched and two MN arrays,
mounted on adhesive foam borders, were inserted into the back of each
rat using ﬁrm ﬁnger pressure. Metformin HCl-loaded reservoirs with a
drug loading of 50mg were applied to the back of the arrays covering
the area exposed to the MNs. To secure the integrated patch in place, an
occlusive dressing layer (Tegaderm™, 3 M, St Paul, Minnesota, USA),
was placed on top of the MNs and Micropore™ tape (3M UK Plc,
Bracknell, Berkshire, UK) was used to wrap the back of the animals. All
animals in the two groups were fasted for the 24 h experiment duration.
Blood samples were taken via tail vein bleeds at pre-deﬁned time in-
tervals: 1, 2, 3, 4 and 24 h with a maximum of 200 μL collected at each
sampling point into heparinized tubes. The MN arrays were kept in
place for 24 h. In accordance with the Project Licence, a staggered study
design was employed, with 8 animals per treatment group and a max-
imum of n=3 blood samples for each rat. Rats were bled at maximum
twice daily.Blood samples were taken from the ﬁrst four rats at 1 h and
3 h. The other four animals were bled at 2 h and 4 h and all animals
(n=8) were sampled at 24 h. These samples were processed as detailed
below, prior to HPLC analysis. Approval for animal experiments was
obtained from the Committee of the Biological Services Unit, Queen's
University Belfast. The work was carried out under Project Licence PPL
2794 and Personal Licence PIL 1466. All in vivo experiments were
conducted according to the policy of the Federation of European La-
boratory Animal Science Associations and the European Convention for
the protection of vertebrate animals used for experimental and other
scientiﬁc purposes, with implementation of the principles of the 3Rs
(replacement, reduction and reﬁnement).
2.10. Blood extraction procedure of metformin HCl and sample preparation
Whole blood was collected from rats into heparinised tubes. To
separate plasma, tubes were centrifuged at 1000 RCF for 10min at 4 °C.
Plasma (100 μL) was subsequently aliquoted into 1.5ml Eppendorf®
tubes and stored at−80 °C until used. Working standard solutions were
prepared by adding an aliquot (20 μL) of metformin HCl solution to
80 μL blank plasma and vortexing for 10 s. For all samples and standard
solutions, acetonitrile (500 μL) was then added to the plasma/standard
mixture and vortex mixed for 10min. This was followed by cen-
trifugation at 14,000 RCF for 10min at 4 °C.The supernatant was then
removed from the Eppendorf® tube and transferred to a disposable glass
culture tube. The sample extract was then dried under a stream of ni-
trogen at 35 °C for 40min using a Zymark TurboVap® LV Evaporator
Workstation (McKinley Scientiﬁc, Sparta, NJ, USA). The residue was
then reconstituted in 100 μL of deionized water. This was vortex mixed
for 30 s, collected in an Eppendorf® and centrifuged at 8000 RCF for
5min at room temperature. The supernatant was then transferred into
an Agilent HPLC vial and 10 μL was injected into the HPLC column.
2.11. Pharmaceutical analysis
Metformin HCl concentrations were determined using HPLC with
UV detection, developed and validated for in vitro and in vivo samples.
In vitro samples were centrifuged at 14,000 rpm using an Eppendorf
MiniSpin® centrifuge (Eppendorf AG, Hamburg, Germany) for 10min
and diluted by PBS (pH 7.4) prior to HPLC analysis. Metformin HCl
concentrations were calculated for in vitro samples by comparing the
area under the curve (AUC) against external standards, using Eq.(1).
=
×
×[Drug]sample [Drug]standard AUC sample
AUC standard
Dilution factor
(1)
Quantiﬁcation of metformin HCl in vitro samples was performed
using reversed-phase HPLC. Chromatographic separation was achieved
using a Waters Cortecs® C18+ column (150×4.6mm, internal dia-
meter (i.d.), with 2.7 μm packing) (Waters Ireland, LTD, Dublin,
Ireland) with isocratic elution and UV detection at 235 nm. The mobile
phase was a mixture of acetonitrile: phosphate buﬀer (containing trie-
thylamine 0.1% and pH adjusted to 3 using phosphoric acid),
(30%:70% v/v). Run time was 7min. The column temperature was
25 °C, the ﬂow rate was 0.3 mL/min and the injection volume was
10 μL.
To account for diﬀerences in volume of plasma obtained from each
rat, Eq.(2) was used for metformin HCl quantitation of in vivo samples.
=
×
×[Drug]sample [Drug]standard AUC sample
AUC standard
volume of standard
volume of sample
(2)
Quantiﬁcation of metformin HCl in in vivo samples was performed
using reversed-phase HPLC. Chromatographic separation was achieved
using a Waters Cortecs® T3 (150×4.6mm (i.d.) with 2.7 μm packing)
analytical column ﬁtted with a guard cartridge of matching chemistry
with isocratic elution and UV detection at 235 nm. The mobile phase
was a mixture of methanol:phosphate buﬀer (containing triethylamine
0.1% and pH adjusted to 3 using phosphoric acid), (3%:97% v/v). Run
time was 30min. The column temperature was 25 °C, the ﬂow rate was
0.4 mL/min and the injection volume was 10 μL.
An Agilent 1200® series system (Agilent Technologies UK Ltd.,
Stockport, UK) was used for all analyses. Agilent ChemStation®
Software B.02.01 was used for chromatogram analysis. Correlation
analysis along with least squares linear regression analysis was per-
formed on the calibration curves generated, enabling determination of
the equations of the line and their coeﬃcients of determination. Limits
of detection (LoD) and limits of quantiﬁcation (LoQ) were determined
using a method based on the standard deviation (SD) of the response
and the slope of the representative calibration curve, as described in the
guidelines from the International Conference on harmonization (ICH)
[28].
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2.12. Statistical analysis
Least squares linear regression analysis, correlation analysis and
calculation of SD of line intercepts and residual SDs were all performed
using Microsoft® Excel® 2013 (Microsoft Corporation, Redmond, USA).
All data were expressed as means± standard deviation. Where appro-
priate, the Mann-Whitney-U test was performed for comparison of two
unpaired groups, when n < 5. The Wilcoxon matched-pairs rank test
was performed for comparison of two paired groups when n < 5. An
unpaired t-test was used for comparison of two groups when n > 5 and
data were normally distributed. The Kruskal-Wallis test with post-hoc
Dunn's test was used for comparison of multiple groups. In all cases,
p < .05 was used to denote statistical signiﬁcance. Statistical analysis
was carried out using GraphPad Prism® version 5.0 (GraphPad Software
Inc., San Diego, California).
3. Results
3.1. Mechanical strength of MNs
The percentage height reduction of MN arrays after applying dif-
ferent compression forces is shown in Fig. 1 (ii). In this mechanical
strength test, there was no signiﬁcant diﬀerence in percentage height
reduction between the diﬀerent applied compression forces (p > .05).
A typical insertion force that would be applied by manual thumb
pressure is around 32 N per array [25]. In the present study, the max-
imum applied compression force was 36.3 N (0.3 N×121 needles).
Even at this force, complete MN array failure was not observed. No
fracturing was observed in MN arrays at any of the applied forces. This
indicated that MN arrays have suﬃcient mechanical strength and are
unlikely to be broken upon insertion into the skin.
3.2. Insertion study using optical coherence tomography
The insertion of MN arrays in Paraﬁlm® M as viewed using OCT is
shown in Fig. 1 (iv). The base plate/ﬁlm surface distance (a), the depth
of MN penetration (b) and the pore width (c) were determined fol-
lowing the application of MN arrays to a validated skin model Paraﬁlm®
M (Table 2). MN penetration depth was 290.83 μm, the pore width was
157.4 μm and the baseplate/ﬁlm surface distance was 182.68 μm. This
indicated that MN arrays penetrated the Paraﬁlm® M consistently.
3.3. Characterisation of lyophilised metformin HCl reservoirs
A number of reservoir formulations were prepared using an iterative
approach. The favoured formulations were those capable of demon-
strating the following characteristics: High metformin HCl drug
loading, homogeneous appearance, robust mechanical integrity for ease
of handling and rapid dissolution in PBS (pH 7.4). The latter property
may suggest that metformin HCl could be readily be released from the
reservoir for delivery through the swollen hydrogel network of the MNs
following skin application.
All metformin HCl reservoirs were homogenous and robust (Table 3
A and B), except formulae F11 and F12, which contained 55% w/w of
metformin HCl and weighed 300mg and 150mg, respectively. These
formulations were overloaded with metformin HCl and drug crystals
were observed on the surface of the reservoirs. According to physical
properties and the dissolution time in PBS (pH 7.4), the optimum for-
mulae were formula F6, which contained 75mg metformin HCl, and
F13, which contained 50mg metformin HCl. F6 and F13 were thus
chosen for in vitro studies.
3.4. Pharmaceutical analysis of metformin HCl
HPLC methods for the quantiﬁcation of metformin HCl in either PBS
(pH 7.4) or rat plasma, were developed and validated according to ICH
guidelines [28]. Calibration curve properties, limits of quantiﬁcation
and detection are presented in Table 4.
3.5. The eﬀect of lyophilisation on metformin HCl stability
The eﬀect of lyophilisation on the stability of metformin HCl was
studied and the percentage recovery values were calculated for both F6
and F13. From formula F6, 93.70% ± 2.68% of metformin HCl was
recovered and 100.70% ± 3.90% was recovered from formula F13.
There was no signiﬁcant diﬀerence in percentage recovery between
formulae F6 and F13 (p= .1). This indicated that lyophilisation had no
signiﬁcant inﬂuence on the stability of metformin HCl for both for-
mulations F6 and F13.
3.6. In vitro permeation of metformin HCl
Permeation of metformin HCl across dermatomed neonatal porcine
skin was signiﬁcantly enhanced by using MN arrays compared to the
control set-up (p < .05). Following application of the combined MN
with F6, for 6 h and for 24 h, 9.71 ± 2.22mg and 28.15 ± 2.37mg
metformin HCl were delivered, respectively, in comparison with
0.34 ± 0.39mg and 0.39 ± 0.39mg delivered from the control set-up
(no MNs) for 6 h and 24 h, respectively (Fig. 2 (i)). In terms of per-
centage delivery, 12.94 ± 2.96% and 37.53 ± 3.17% of metformin
HCl was delivered at 6 h and 24 h, respectively, in comparison to the
control set-up, which delivered 0.45 ± 0.52% and 0.52 ± 0.52% at
6 h and 24 h, respectively.
Following application of the combined MN and F13, for 6 h and for
24 h, 10.04 ± 1.92mg and 23.25 ± 3.58mg metformin HCl was de-
livered, respectively, in comparison with 0.85 ± 0.68mg and
1.01 ± 0.84mg delivered from the control set-up (no MNs), for 6 h and
24 h, respectively (Fig. 2 (ii)). In terms of percentage delivery, at 6 h
and 24 h, 20.07 ± 3.84% and 46.50 ± 7.16% of metformin HCl was
delivered, respectively, in comparison to the control set-up, which de-
livered 1.71 ± 1.36% and 2.01 ± 1.68%, at 6 h and 24 h, respec-
tively.
Fig. 3 (i), (ii) shows digital images of a MN array before swelling in
PBS (pH 7.4) and after swelling in PBS (pH 7.4) for 24 h, re-
spectively.This indicates the now well-known-capacity of such systems
to swell [1].
Formula F13 was chosen for the in vivo study, as it had faster dis-
solution (3min) compared to F6, which had a dissolution time of 6min.
Rapid dissolution of a drug reservoir in PBS (pH 7.4) indicates that
metformin HCl could readily be released from the reservoir and thus be
available for permeation through a swollen hydrogel network. In ad-
dition, F13 had a lower thickness (0.90mm) compared to F6
(2.47 mm). Reservoir thickness is an important aspect. In previous in
vivo work within our Group, it was found that MN patches need to be
relatively thin to ensure that rats will tolerate them for 24 h. If the patch
is too bulky and cumbersome, it can interfere with the rat's natural
behaviour and they will strive to remove it over the course of the study
period. Furthermore, when considering this delivery system as a ﬁnal
product in humans, it is likely that patients would prefer patches that
do not extend signiﬁcantly outwards from the surface of the skin.
Table 2
OCT assessment of MNs penetration following application to Paraﬁlm® M in
vitro.
Baseplate/ﬁlm
surface distance
(μm) (a)
MN penetration
depth (μm) (b)
Pore width (μm) (c)
Mean ± SD
(n=12)
182.68 ± 27.09 290.83 ± 40.23 157.40 ± 19.49
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Table 3
Characteristics of lyophilised metformin HCl reservoirs.
Formula Thickness (mm) Dissolution time (min) Physical properties Morphology
A.
F1 3.2 16 Homogeneous, and robust reservoirs
F2 2.4 12 Homogeneous, and robust reservoirs
F3 3.7 12 Homogeneous, and robust reservoirs
F4 2.3 9 Homogeneous, and robust reservoirs
F5 4.1 8 Homogeneous, and robust reservoirs
F6 2.5 6 Homogeneous, and robust reservoirs
B.
F7 4.5 12 Homogeneous, and robust reservoirs
F8 2.7 10 Homogeneous, and robust reservoirs
F9 4.3 17 Homogeneous, and robust reservoirs
(continued on next page)
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3.7. In vivo study
Each rat in the MNs transdermal treatment group had two in-
tegrated MN patches applied to their back. As can be seen from the
plasma proﬁle (Fig. 4 (i)), metformin HCl was detected in rat plasma at
1 h post MN application at a concentration of 0.62 ± 0.51 μg/mL. The
concentration increased to 3.76 ± 2.58 μg/ml at 3 h and then de-
creased slightly at 4 h to 3.21 ± 0.69 μg/mL. However, a maximal
concentration of 3.77 ± 2.09 μg/ml was achieved for the 100mg dose,
the total of two applied 50mg MN patches, at 24 h.
Each rat in the oral control group received an oral solution of
metformin HCl 100mg/kg. As can be seen from the plasma proﬁle
(Fig. 4 (ii)), metformin HCl was detected in the rat plasma at 1 h post-
Table 3 (continued)
Formula Thickness (mm) Dissolution time (min) Physical properties Morphology
F10 2.8 16 Homogeneous, and robust reservoirs
F11 5.7 6 Overloaded reservoirs with metformin HCl crystals on surface
F12 2.3 5 Overloaded reservoirs with metformin HCl crystals on surface
F13 0.9 3 Homogeneous, and robust reservoirs
Table 4
Properties of calibration curves for quantiﬁcation of metformin HCl in (i) PBS
(pH 7.4) in vitro and (ii) rat plasma in vivo, along with limits of detection and
quantiﬁcation.
Method Slope y-Intercept R2 σ LoD LoQ
i)In vitro (PBS
(pH 7.4))
159.36 114.72 0.9994 77.95 1.47 (μg/
mL)
4.89 (μg/
mL)
ii)In vivo (rat
plasma)
0.08 12.79 0.9995 3.14 132 ng/
mL
402 ng/
mL
Fig. 2. (i) In vitro cumulative amount of metformin HCl permeated across dermatomed neonatal porcine skin from reservoir formula F6 (75mg) in combination with
hydrogel-forming MNs in comparison to the control setup with no MNs. (ii) In vitro cumulative amount of metformin HCl permeated across dermatomed neonatal
porcine skin from reservoir formula F13 (50mg) in combination with hydrogel-forming MNs in comparison to the control setup with no MNs, (means ± SD, n=6).
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oral gavage administration at a concentration of 4.97 ± 2.57 μg/mL.
The concentration increased to a maximum of 6.25 ± 2.94 μg/m, at
2 h. At 4 h, metformin HCl concentration decreased to 1.42 ± 1.37 μg/
ml and continued to decrease until the 24 h endpoint.
Fig. 5 shows the in vivo MN application process. Fig. 5 (iii) shows
MN arrays that have swelled extensively, with each drug reservoir
having dissolved fully at 24 h. MN arrays were removed intact from the
skin, leaving no polymeric residues behind. No oedema was observed at
the site of application. Following removal of patches, some rats
displayed only minimal erythema, which resolved fully within 1 h post
MN patch removal.
Pharmacokinetic parameters are presented in Table 5. Css (steady-
state plasma concentration) was calculated using Eq.(3), where AUC is
the area under the plasma concentration/time curve and t is time.
=
−C AUC
tss
t0 24
(3)
Tmax (time of maximum concentration observed) was 24 h in the MN
Fig. 3. Digital images of (i) MN array before swelling in PBS (pH 7.4). (ii) MN array after swelling in PBS (pH 7.4) for 24 h.
Fig. 4. (i) The in vivo plasma proﬁles of metformin
HCl following application of hydrogel-forming MNs
and solid metformin HCl-containing reservoir (F13)
integrated patches at a dose of 100mg. (ii) The in
vivo plasma proﬁles of metformin HCl following oral
gavage at a dose of 100mg/kg of rat weight,
(means ± SD, n at least= 4, for 24 h, n=8).
Fig. 5. Representative images of in vivo study displaying MNs application process. (i) Shaving the rat hair on the back, (ii) MN arrays with drug reservoir patches
applied in situ, (iii) MN arrays removed from the back of a rat after 24 h with the adhesive backing removed and the swollen MN arrays.
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transdermal-treated rat group and Css was 3.2 μg/mL.
Relative transdermal bioavailability of metformin HCl using hy-
drogel-forming MN was determined according to Eqs.(4) and (5) by
dividing AUC of the plasma proﬁle of metformin HCl in the MNs
transdermal treatment group by AUC of the plasma proﬁle of metformin
HCl in the oral control group. Where AUCt0−24 is the area under the
curve from zero time to 24 h, F is the bioavailability, X0 is the initial
dose, Cl is the clearance of metformin HCl.
=−AUC
FX
Clt0 24
0
(4)
=
−
−
AUC MNs
AUC Oral
FX
FX
( )
( )
t
t
MNs
oral
0 24
0 24
0 ( )
0 ( ) (5)
In the MNs transdermal treatment group, X0 was 100mg (two MN
patches), X0 in the oral control group was 22.4 mg, (at an oral dose of
100mg/kg, the average weight of rats in the oral gavage group was
224.5 g ± 16.57 g). Therefore, the relative transdermal bioavailability
of metformin HCl using hydrogel-forming MNs is [F(MNs)/F(oral)] and
it was calculated as 0.6 of the oral bioavailability (F(oral)). The oral
bioavailability of metformin HCl (F(oral)) is known to be approximately
50%, or 0.5 [23]. F(MNs) is the transdermal bioavailability of met-
formin HCl when delivered using our MNs and it was calculated as 0.3
(30%). This means that approximately 30mg of metformin HCl was
delivered transdermally using the MN patches during the study.
To achieve equivalent delivery of metformin HCl from a 500mg oral
tablet, a hydrogel-forming MN patch containing 833mg would be re-
quired. As these MN systems contain 50mg/MN patch and has an array
area of 0.49 cm2, this means that the expected patch size that the pa-
tient may need to apply to their skin is around 8 cm2 (containing
833mg metformin HCl) every 24 h.
4. Discussion
Presented in this study is a novel combination of a metformin HCl-
containing lyophilised drug reservoir and a hydrogel-forming MN array
and aims to enhance the transdermal delivery of this antidiabetic drug.
Hydrogel-forming MNs have demonstrated the ability to enhance the
transdermal delivery of many therapeutic substances with a wide range
of physicochemical properties [1,3,4]. This highlights the versatility of
this MN type and shows that hydrogel-forming MNs have considerable
promise for commercial success. When inserted into the skin, hydrogel-
forming MNs are in contact with interstitial ﬂuid. MNs swell and create
porous aqueous microconduits through which drug substances can
diﬀuse and reach the dermal microcirculation. The aqueous network
created by these MNs is suitable for transdermal delivery of drugs with
a relatively high degree of water solubility, for example, metformin
HCl.
The primary objectives of this work included formulating a well-
formed lyophilised drug reservoir using biocompatible materials with a
high drug loading of metformin HCl, rapidly dissolving in aqueous ﬂuid
and yielding high drug recovery. The ingredients selected for the lyo-
philised drug reservoir preparation have been previously used and
shown to have the required properties [3]. To characterise the drug
reservoirs, physical tests were conducted to assess the suitability of the
formulation for use in the transdermal application. Among the prepared
drug reservoirs formulations, two were selected (F6, F13) based on
formulation integrity, high metformin HCl content and rapid dissolu-
tion rates in PBS (pH 7.4).MN swelling, followed by ﬂuid movement
through the swollen microstructures, is the key factor in facilitating
drug reservoir dissolution and in creating the micropores though which
drug diﬀusion occurs. The swelling behaviour of hydrogel-forming MNs
in PBS (pH 7.4) has been evaluated previously by our Group [3]. In
addition, MNs should have suﬃcient mechanical strength and demon-
strate consistent insertion properties to achieve successful application
of MN array into the dermatomed porcine skin in vitro and rat skin in
vivo.
MN inserted eﬃciently into the validated skin model Paraﬁlm® M
[25] [1–3,24,25]. Hydrogel-forming MNs also showed suﬃcient me-
chanical strength to penetrate skin in vitro and in vivo, consistently.
The in vitro permeation studies carried out with formulae F6 and
F13 with hydrogel-forming MN arrays across neonatal porcine skin via
the Franz diﬀusion cell technique demonstrated that for F6,
12.9 ± 2.96% (9.71 mg) and approximately 37.5 ± 3.17%
(28.15mg) of metformin HCl loadings were successfully delivered at
6 h and 24 h, respectively. For F13, 20.07 ± 3.84% (10.04mg) of
metformin HCl was delivered at 6 h and approximately 46.50 ± 7.16%
(23.25mg) of the metformin HCl was successfully delivered at 24 h.
Following insertion, the MNs imbibe ﬂuid, with subsequent swelling
and expansion of the hydrogel matrix, this facilitated the diﬀusion of
metformin HCl drug molecules through the micropores created in the
skin. The imbibed ﬂuid causes dissolution of the lyophilised drug re-
servoir. With time, MN swelling increased and caused higher amounts
of metformin HCl to permeate through the MN microchannels. Upon
visual inspection of the Franz cell donor compartment post-experiment,
it was obvious that there was complete dissolution of the drug reservoir.
A safe oral dose of metformin HCl for rats is 100–200mg/kg [26].
Taking into consideration the mean weight of a rat (250 g) and the
mean oral bioavailability of metformin HCl (50–60%) [25], it was es-
timated that, for a dose of 100–200mg/kg, 15–30mg would reach the
systemic circulation. To ensure a safe oral dose was employed, 100mg/
kg was selected, thus minimizing the chance of toxicity and side eﬀects.
Following the in vitro permeation studies, it was clear that
46.50 ± 7.16%, (23.25 ± 3.58mg) of metformin HCl in formulation
F13 was released into the donor compartment. Using this as a guide for
planning in vivo transdermal dosing, assuming 25–30% of metformin
HCl will be successfully delivered to the rats over 24 h, MN patches
could, therefore, include 100mg metformin HCl.
The results obtained in the in vivo experiment suggest that the use of
hydrogel-forming MN arrays oﬀer the potential for successful trans-
dermal delivery of metformin HCl. It is important to highlight that
metformin HCl plasma concentration was shown to be sustained over
24 h. This may indicate that the drug continues to be released from the
MN patch while it was being cleared from the body of the rats.
Once the drug has diﬀused through the MNs, uptake by the dermal
microcirculation is likely to be rapid. By the end of the experiment
runtime, it was noted that an almost constant plasma concentration of
metformin HCl was maintained. Metformin HCl delivered from an in-
tegrated MN patch yielded plasma concentrations in the rat model,
reaching the target therapeutic concentration in humans of (1–5) μg/ml
[29,30].
The relative transdermal bioavailability of metformin HCl when
using hydrogel-forming MNs was estimated as 0.6 of its oral bioavail-
ability. The transdermal bioavailability of metformin HCl when using
hydrogel-forming MNs was estimated as 0.3. This means that 30% of
the drug loading would be delivered within 24 h.It is recognized that
the dose of metformin HCl used in this study is much lower than the
oral human dose. In the plasma proﬁle of metformin HCl, it is obvious
that the steady-state concentration was achieved within the duration of
Table 5
Pharmacokinetic parameters of metformin HCl in the MNs transdermal treat-
ment group and in the oral control group (means ± SD, n at least= 4, for 24 h,
n=8).
Parameter MNs (dose= 50mg/MN
patch)
Oral (dose= 100mg/kg)
AUC (μg·h/mL) 77 31.29
Tmax (h) 24 2
Cmax (μg/mL) 3.77 ± 2.09 6.25 ± 2.94
Css (μg/mL) 3.2 Cannot be calculated for single
oral dose
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this experiment (24 h). In transdermal delivery, the rate of absorption is
slower than oral delivery, due to the lag time associated with initial
swelling of MN patches.Actually, it is important to consider that the
pharmacokinetics of a rat and a human are quite diﬀerent, but the re-
sults of this small-scale study are promising. When cautiously extra-
polated, a human metformin HCl dose of 500mg could be achieved
with a patch size of approximately 8 cm2, containing a drug load of
833mg metformin HCl.
Potential approaches to improve the bioavailability of transder-
mally-delivered metformin HCl in future may include changing the type
of crosslinker. Hydrogel-forming MNs using a higher molecular weight
crosslinker could increase the swelling of MNs. Further changes to the
type of drug reservoir may also further enhance delivery of metformin
HCl. Hydrogel-forming MNs are clearly a promising technology that
could be used to enhance transdermal delivery of a range of therapeutic
substances [31]. The aim of this study was to establish preliminary data
to investigate the potential for transdermal delivery of metformin HCl
by hydrogel-forming MNs. We have provided ‘proof of concept’ evi-
dence that metformin HCl can be delivered transdermally using hy-
drogel-forming MNs.
5. Conclusion
The work presented here reports successful design and evaluation of
a combined hydrogel-forming MN array / drug reservoir transdermal
patch. In in vivo experiments, therapeutic doses of metformin HCl were
delivered to rats in a sustained manner, highlighting the potential of
this delivery route for metformin HCl administration. This type of
system may provide an alternative mode of delivery for patients and
help to minimize gastrointestinal side eﬀects and small intestine ab-
sorption variations associated with conventional oral delivery. In
pathway to commercialization of this technology, especially when
manufactured on a large scale, cost will be an important issue and will
need to be minimized, especially for generic, oﬀ-patent drugs, such as
metformin, where proﬁt margins are tight. Hydrogel-forming MNs re-
present a promising technology that could be used for transdermal
delivery of many other established drugs with high oral doses. If clinical
beneﬁts can be shown, then perhaps healthcare providers would be
willing to pay slightly more than they currently do for oral medicines.
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